CHAN, DENISE S. B.,陈 素碧,陳 素碧,LEE, MING TSUNG,李 铭聪,李 銘聰,YOON, WENG LI,袁 永丽,袁 永麗,LAU, JOHNSON YIU NAM,刘 耀南,劉 耀南
申请号：
TW105131091
公开号：
TW201711680A
申请日:
2016.09.26
申请国别(地区):
TW
年份:
2017
代理人:
摘要：
A pharmaceutical composition comprises a taxane in a mixture of first and second surfactants. The absorption of the taxane is increased from the pharmaceutical composition is greater than the sum of the absorption of docetaxel from either the first or the second surfactant. The increase in absorption is especially enhanced when the ratio of the first surfactant to the second surfactant in the pharmaceutical composition is between 60:40 and 85:15 by weight, and the total surfactant weight does not exceed 98% of the total weight. Polysorbate 80, polysorbate 20, and caprylocaproyl polyoxylglycerides serve as suitable first surfactants, and polysorbate 80 or polyethyoxylated castor oil serve as suitable second surfactants. The stability of the pharmaceutical composition may be enhanced by further including a stabilizer (e.g., citric acid and/or ascorbic acid).醫藥組合物包含在第一表面活性劑和第二表面活性劑之混合物中的紫杉烷。來自醫藥組合物之紫杉烷的吸收度之增加係大於來自第一表面活性劑或第二表面活性劑其中之一的歐洲紫杉醇的吸收度的總和。當醫藥組合物中第一表面活性劑與第二表面活性劑的重量比在60:40和85:15之間,且總表面活性劑重量不超過總重量的98%時,特別增強了吸收度的增加。聚山梨醇酯80、聚山梨醇酯20及辛醯己醯聚氧甘油酯可作為合適的第一表面活性劑,而聚山梨醇酯80或聚乙氧基化蓖麻油可作為合適的第二表面活性劑。醫藥組合物的穩定性可透過進一步包含穩定劑(例如為檸檬酸及/或抗壞血酸)來提高。
